SCHEMBL6071880

SCHEMBL6071880

C#CC(=O)Oc1ccc(C)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
THRA P10827 1/20 0.54
THRB P10828 1/20 0.54
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.43
KMT2A Q03164 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTK2B Q14289 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PRSS1 P07477 1/20 0.40
ACR P10323 1/20 0.40
ACHE P22303 1/20 0.39
MAPT P10636 1/20 0.39
BCHE P06276 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3859415 0.83 THRA (0.54) LMNATHRATHRBALDH1A1GAA
SCHEMBL4544923 0.83 LMNA (0.61) LMNAALDH1A1GAAKMT2ACYP1A2
SCHEMBL6653843 0.81 THRB (0.51) LMNATHRATHRBGAAKMT2A
SCHEMBL10928698 0.79 ELANE (0.50) LMNATHRATHRBKMT2ARXFP1
SCHEMBL12314506 0.79 LMNA (0.57) LMNAALDH1A1GAAKMT2ACYP1A2
SCHEMBL16087039 0.79 THRA (0.50) THRATHRBALDH1A1KMT2ACYP1A2
SCHEMBL3864698 0.79 THRA (0.50) THRATHRBKMT2ACYP1A2CYP2C19
SCHEMBL31711461 0.79 THRB (0.50) LMNATHRATHRBALDH1A1GAA
SCHEMBL9260093 0.79 THRA (0.50) LMNATHRATHRBALDH1A1KMT2A
SCHEMBL14922470 0.79 THRA (0.50) THRATHRBALDH1A1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1183133-C 2-amino-6-anilino-purines and their use as medicaments ��˹��ŵ�� 2005-01-05 CN claimed
CN-1340054-A 2-amino-6-anilino-purines and their use as medicaments NOVARTIS AG (CH) 2002-03-13 CN claimed
CN-111203279-B Sandwich nano material ZIF-8@Au 25 @ ZIF-67 and preparation method and application thereof 安徽大学 2023-04-25 CN disclosed
CN-109438301-A A kind of synthetic method of α-trifluoromethylthio substituted aroma ketone compounds 江南大学 2019-03-08 CN disclosed
CN-104151278-B The synthetic method of 1-phenyl-2,3-naphthalene dicarboxylic acids acid anhydride and derivative thereof SHAANXI NORMAL UNIVERSITY (CN) 2016-04-06 CN disclosed
CN-104151278-A Synthesis method of 1-phenyl-2,3-naphthalene dicarboxylic anhydride and derivatives thereof UNIV SHAANXI NORMAL 2014-11-19 CN disclosed
US-20120202794-A1 COMPOUNDS PHARMASSET, INC. (US) 2012-08-09 US disclosed
WO-2012103113-A1 PYRAZINE AND IMIDAZOLIDINE DERIVATIVES AND THEIR USES TO TREAT HEPATITIS C GILEAD PHARMASSET, LLC (US) 2012-08-02 WO disclosed
US-20060160794-A1 Tachykinin receptor antagonists ELI LILLY AND COMPANY 2006-07-20 US disclosed
CN-1183133-C 2-amino-6-anilino-purines and their use as medicaments ��˹��ŵ�� 2005-01-05 CN disclosed
CN-1340054-A 2-amino-6-anilino-purines and their use as medicaments NOVARTIS AG (CH) 2002-03-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202794-A1 COMPOUNDS HAVCR2, MAVS, GOT2 LMNA 4549/4885THRA 4493/4885THRB 4060/4885
US-20060160794-A1 Tachykinin receptor antagonists TACR1, TACR2, PROKR1 LMNA 4479/4885THRA 681/4885THRB 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.